Results 121 to 130 of about 22,482 (226)

Resolution of Angiographic Macular Leakage with Faricimab Versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE.

Ophthalmology Retina
PURPOSE To evaluate if dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor-A (VEGF-A) inhibition with faricimab resulted in greater macular leakage resolution versus aflibercept in patients with diabetic macular edema (DME).
R. Goldberg, Florie Mar, Karl G. Csaky, Manuel Amador, A. Khanani, K. Gibson, A. Kolomeyer, D. Sim, Toshinori Murata, Tracey Wang, P. Udaondo, Audrey Souverain, Y. Shildkrot, S. Vujosevic, E. Nudleman, S. Sivaprasad   +15 more
semanticscholar   +1 more source

Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study [PDF]

Debdulal Chakraborty,1 Subhendu Boral,1 Tushar Kanti Sinha,1 Arnab Das,1 Angshuman Mukherjee,1 Saptorshi Majumdar,1 Ranabir Bhattacharya,2 Ritobroto Maitra3 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India ...
Majumdar S, Chakraborty D, Bhattacharya R, Boral S, Das A, Mukherjee A, Maitra R, Sinha TK   +7 more
core  

Acceptable price per aflibercept injection.

, 2018
Which price is acceptable for one aflibercept injection depends on what society is willing to pay. The graph shows that at a willingness-to-pay of €80,000 per QALY aflibercept should cost no more than €533.
Maroeska M. Rovers (120760), Carel B. Hoyng (552359), Gert Jan van der Wilt (659529), Freekje van Asten (659525), Charlotte T. J. Michels (5233892), B. Jeroen Klevering (659530), Janneke P. C. Grutters (5233889)   +6 more
core   +1 more source

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum]

, 2017
Korol AR, Zborovska O, Kustryn T, et al. Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study. Clin Ophthalmol.
Kustryn T, Korol AR, Zborovska O, Dorokhova O, Pasyechnikova N   +4 more
core  

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study

Eye
There are no data on pharmacokinetics, pharmacodynamics, and immunogenicity of intravitreal aflibercept in preterm infants with retinopathy of prematurity (ROP).
A. Stahl, Noriyuki Azuma, Wei-Chi Wu, Domenico Lepore, E. Sukgen, Hidehiko Nakanishi, J. Mazela, Sergio Leal, Alexander Pieper, Sarah Schlief, Thomas Eissing, Kenneth C Turner, An Zhao, Julia Winkler, J. Höchel, Evra Köfüncü, Torsten Zimmermann   +16 more
semanticscholar   +1 more source

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

Life
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, Franziska Eckardt, Anna Lorger, Viktoria Deiters, Johannes Schiefelbein, Julian Elias Klaas, Benedikt Schworm, Siegfried G. Priglinger, Jakob Siedlecki   +10 more
doaj   +1 more source

Efficacy of Faricimab vs Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase 3 YOSEMITE/RHINE Trials.

Ophthalmology (Rochester, Minn.)
PURPOSE DRCR.net Protocol T data suggest the response to treatment among patients with diabetic macular edema (DME) may vary depending on baseline best-corrected visual acuity (BCVA).
M. Zarbin, D. Tabano, Ayesha Ahmed, Manuel Amador, Allan Ding, Nancy M Holekamp, Xiao-Yu Lu, I. Stoilov, Ming Yang   +8 more
semanticscholar   +1 more source

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis

, 2017
Kimberly Spooner,1–3 Thomas Hong,1,2 Wijeyanthy Wijeyakumar,1–3 Andrew A Chang1–3 1Sydney Retina Clinic & Day Surgery, 2Sydney Institute of Vision Science, Sydney, 3Save Sight Institute, Department of Ophthalmology, University of ...
Chang AA, Spooner K, Hong T, Wijeyakumar W   +3 more
core  

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Therapeutic Advances in Ophthalmology
What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in The Lancet scientific journal. • Wet age-related macular degeneration (or AMD) is a long-term eye disease in which abnormal blood vessels grow
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong   +20 more
doaj   +1 more source

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +1 more source